Journal Article

A designer peptide against the EAG2-Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma

Beilhartz, Greg L, Kong, Tian, Liu, Hongwei, Bahrampour, Shahrzad, Morioka, Malia S, Chen, Xiaodi, Zhao, Hongyu, Li, Xuejun, Huang, Xi, Song, Yuanquan, Kim, Tae-Hee, Wanggou, Siyi, Jung, Geena, Dong, Weifan, Xiong, Yi, Chen, Xin, Kim, Ji-Eun, Schramek, Daniel, Yang, Qi, Fekete, Adam, Dirks, Peter B, Melnyk, Roman A, Wang, Lu-Yang, He, Ye

2023

Overview

Glioblastoma (GBM) is an incurable brain cancer that lacks effective therapies. Here we show that EAG2 and Kvβ2, which are predominantly expressed by GBM cells at the tumor-brain interface, physically interact to form a potassium channel complex due to a GBM-enriched Kvβ2 isoform. In GBM cells, EAG2 localizes at neuron-contacting regions in a Kvβ2-dependent manner. Genetic knockdown of the EAG2-Kvβ2 complex decreases calcium transients of GBM cells, suppresses tumor growth and invasion and extends the survival of tumor-bearing mice. We engineered a designer peptide to disrupt EAG2-Kvβ2 interaction, thereby mitigating tumor growth in patient-derived xenograft and syngeneic mouse models across GBM subtypes without overt toxicity. Neurons upregulate chemoresistant genes in GBM cells in an EAG2-Kvβ2-dependent manner. The designer peptide targets neuron-associated GBM cells and possesses robust efficacy in treating temozolomide-resistant GBM. Our findings may lead to the next-generation therapeutic agent to benefit patients with GBM.

• Publisher: Nature Publishing Group
• Subject: Animals / Brain cancer / Cancer therapies / Cell growth / Disease Models, Animal / Ether-A-Go-Go Potassium Channels - therapeutic use / Glioblastoma - drug therapy / Glioma / Humans / Mice / Neurons / Neurons - pathology / Peptides / Peptides - therapeutic use / Potassium / Signal transduction / Temozolomide - pharmacology / Temozolomide - therapeutic use / Tumors